Bernstein raised AstraZeneca's target price, with core incremental upside coming from non-oncology ATTR-CM opportunities.
AI summary card
Bernstein raised AstraZeneca's target price, with core incremental upside coming from non-oncology ATTR-CM opportunities.
The report maintains AstraZeneca's Outperform rating and raises the target price from 18,600 GBp to 18,900 GBp, arguing that Wainua and cliramitug could drive the company to lead in the roughly $20bn peak ATTR market.
- Bernstein raised AstraZeneca's target price to 18,900 GBp, representing about 30% upside versus the July 2, 2026 close of 14,538 GBp.
- The report raised AstraZeneca's 2036 ATTR business forecast by 60% to about $10bn, with Wainua seen as a potential second-largest non-oncology drug.
- The analysis states that AstraZeneca has positioned across three proven ATTR mechanisms: stabilizers, gene silencers, and depleters, while combination therapy and the Alexion rare disease commercial foundation create a competitive edge.
- Valuation still uses an average of DCF and EV/EBITA, with DCF at £156/share and EV/EBITA at £223/share, leading to a combined target price of £189/share.
Report interpretation
Overview
This report focuses on the upside in AstraZeneca's non-oncology business, especially the ATTR-CM market. Bernstein believes that although non-oncology Phase III data has been positive since Q3 2025, this business has not yet been fully recognized by the market; however, the non-oncology business contributes most of the incremental sales CAGR for the group in 2026-2031 and may offer full upside potential to total revenue.
Core views
The core view is that AstraZeneca is likely to lead in the roughly $20bn peak ATTR market: the company has three validated ATTR mechanisms in place, and if Wainua's CardioTTRansform Phase III data shows a positive readout in 2H26, significant upside could be unlocked; cliramitug as a depleter-mechanism drug could also expand the market and boost the company share. The report therefore raised AstraZeneca's 2036 ATTR business forecast to about $10bn and kept a constructive rating.
Analysis framework
The report combines expert interviews, channel research, bottom-up patient modeling, U.S. prescription-data cross checks, competitor comparisons, scenario analysis, and DCF and EV/EBITA valuation frameworks to assess ATTR-CM market size, Wainua and cliramitug peak sales, share changes versus Alnylam and peers, and the impact of those changes on the target price.
Methodology notes
The target price is the simple average of DCF valuation and EV/EBITA multiple valuation.
DCF uses 8% WACC and a 2.5% terminal growth rate; EV/EBITA valuation keeps a 60% premium relative to European peers.
ATTR sales forecasts are derived from patient numbers, diagnosis rates, treatment penetration, market share, and pricing.
The report cross-validates with U.S. prescription data and raises expectations for ATTR market expansion and AstraZeneca share based on rare-disease precedents.
Uses 2035 EBIT as a proxy metric in DCF to measure upside and downside.
The report calculates 167% upside in bull case and 97% downside in bear case; contribution from approved drugs drives most of the upside and part of the downside.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- AstraZeneca PLCThe company and core investment target covered in the report.
- Strengths
- Has a leading R&D engine, strong commercial execution, an ATTR multi-mechanism portfolio, and an Alexion rare-disease base.
- Weaknesses
- Some upside is expected to materialize mainly from 2028 onward, with limited near-term valuation multiple change.
- Comparison
- It enjoys a valuation premium versus European peers; the report says its 5-year forward sales re-rating still appears inexpensive relative to global peers.
- Risks
- If key drug data, commercialization, or group margins fall short of expectations, the target price and earnings forecasts may come under pressure.
- WainuaAstraZeneca's key gene silencer in the ATTR-CM market.
- Strengths
- If CardioTTRansform Phase III is successful, it could establish best-in-class status and become AstraZeneca's second-largest non-oncology drug.
- Weaknesses
- The main upside depends on the key 2H26 Phase III data being delivered.
- Comparison
- If it shows better efficacy in patients already eligible for silencer therapy, it could take share from Alnylam's Amvuttra.
- Risks
- Clinical data below expectations or improved competitor convenience may limit share gains.
- cliramitugA depleter-mechanism drug in AstraZeneca's ATTR-CM pipeline.
- Strengths
- Has first-in-class potential and could clear ATTR cardiac deposits that drive symptoms.
- Weaknesses
- Still in clinical progression and commercial proof-of-concept stage.
- Comparison
- Complements stabilizers and silencers, strengthening AstraZeneca's full ATTR product portfolio.
- Risks
- If subsequent data or pricing falls short of expectations, sales forecasts may be revised down.
- Alnylam / AmvuttraAn important competitive reference in ATTR-CM.
- Strengths
- Amvuttra already has relatively high consensus peak-sales expectations, and nucresiran may improve dosing convenience.
- Weaknesses
- The report suggests nucresiran may be internally cannibalizing Amvuttra rather than being entirely incremental.
- Comparison
- AstraZeneca is seen as having long-term leadership potential due to combination therapy and stronger data.
- Risks
- If Alnylam's next-generation silencer nucresiran commercializes stronger than expected, AstraZeneca's share could be constrained.
Key data
- RatingOutperformBernstein maintains a constructive rating on AstraZeneca.
- Target Price18,900 GBpRaised from prior target price of 18,600 GBp.
- Closing Price14,538 GBpAs of 2 Jul 2026.
- Implied Upside30%Calculated from target price versus closing price.
- ATTR Peak Market Opportunityaround $20bnThe report discusses the peak market size for ATTR-CM-related drugs.
- AstraZeneca 2036 ATTR Forecastaround $10bnThe report states this is raised 60% from the previous forecast.
- Wainua 2036 Base Forecast$6.2bnRisk-adjusted base-case forecast is raised 20%.
- cliramitug 2036 Base Forecast$3.3bnForecast is raised to about four times the prior level.
- DCF Valuation£156/shareRaised from previous £148/share.
- EV/EBITA Valuation£223/shareAveraged with DCF to form a target price of about £189/share.
Impact & implications
If Wainua delivers a strong readout in the 2H26 CardioTTRansform Phase III trial, AstraZeneca could gain greater share in the ATTR-CM market and make non-oncology the main source of group-wide revenue upgrades. For investors, the report emphasizes that the market may be underestimating AstraZeneca's non-oncology pipeline, rare-disease commercialization capability, and quality of long-term sales growth.
Risks
- Wainua's CardioTTRansform Phase III data is below expectations and fails to establish best-in-class status.
- ATTR-CM diagnosis rates, market expansion, or treatment penetration are lower than model assumptions.
- Alnylam's next-generation silencer nucresiran brings significant convenience gains and strengthens competition.
- Datroway, Enhertu, or group margin performance is worse than the report's model assumptions.
- Early pipeline assets fail to advance to late-stage development or commercialization.
What to watch
- Wainua CardioTTRansform Phase III data readout in 2H26.
- Sales ramp speed and market share trajectory for Wainua and cliramitug through the 2030s.
- ATTR-CM diagnosis-rate improvements, physician awareness, and combination therapy usage trends.
- Alnylam nucresiran launch timing and the extent of cannibalization of Amvuttra.
- Actual contribution of AstraZeneca's non-oncology business to the group’s 2026-2031 sales CAGR.